September 16th 2024
Your daily dose of the clinical news you may have missed.
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
September 9th 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
Breaking Down Kidney Disease: From Guidelines to Prognostic Profiling
In Older Adults with T2D, Clinical Decision Support Tool Can Reduce Hypoglycemia
In adults older than age 65 years with T2D, a simple clinical decision support tool plus shared decision making reduced hypoglycemic episodes by half.
Daily Dose: Waist-to-Hip Ratio Better Predictor for Mortality than BMI?
FDA Adds New Warnings to Labeling for Ozempic
The addition of ileus as a potential adverse event associated with the GLP-1 mimetic is not the first required for the class by the regulator.
One or More Cardiac, Renal, or Metabolic Conditions Affect 25% of US Adults
The prevalence of cardiac, renal, and metabolic conditions has significantly increased over 20 years and so has the number of US adults who have all 3.
GLP-1 Mimetics, SGLT-2 Inhibitors Understudied in Black Populations in Pivotal Trials, Benefits Questioned
Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.
Biosimilar Liraglutide Noninferior to Reference Product in Persons with Type 2 Diabetes: Phase 3 Trial
The biosimilar to the GLP-1 mimetic Victoza proved noninferior for reduction of HbA1c and had similar positive effects on body weight, lipids, and blood pressure.
Waist-to-Hip Ratio More Consistently Associated with Mortality vs BMI: New Research
Waist-to-hip ratio was more powerfully and consistently associated with risk of all-cause mortality than BMI or FMI, but can it replace BMI as a clinical indicator?
Abbott, WeightWatchers Announce App Integrating FreeStyle Libre 2 CGM Data
The new app is designed to help persons with diabetes understand how food and activity impact blood glucose levels and to revise behavior accordingly.
Why is Wound Care Falling to Primary Care?
Overscheduled and undertrained, primary care clinicians shoulder a significant portion of the US wound care burden. Author Nima Ahmadi offers a technology-based solution.
Daily Dose: "Night Owls" Less Healthy, at Higher Risk for T2D
PCOS Ups Risk of Maternal, but Not Neonatal Adverse Outcomes in Women with T2D in Pregnancy
Women with PCOS and T2D in pregnancy were at greater risk for high insulin requirements, excess weight gain, and worsening of pregestation hypertension if treated with metformin.
Rise in GLP-1 Mimetic Demand Will Continue as Pluripotency Expands
The class of GLP-1 receptor agonists and similar agents, originally approved to treat type 2 diabetes, also reduce body weight and reduce CVD risk; what's next?
Evening Chronotype in Women Linked with Unhealthy Lifestyle, Increased Risk for Type 2 Diabetes
Women with an evening vs morning chronotype were 54% more likely to have unhealthy lifestyles that in turn accounted for a significant increased risk for diabetes.
Biden Administration Announces First 10 Prescription Drugs Slated for Price Negotiations
The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.
Daily Dose: Semaglutide May Benefit 93 Million US Adults
A daily dose of clinical news on Patient Care you may have missed.
Cardiorenal Risk Estimates in T2D Mediated by Common Biomarker Response to Canagliflozin
Reduction in levels of 4 biomarkers was correlated with lower risk of composite cardiorenal outcomes in the CREDENCE trial, suggesting use of the panel to augment current risk assessment tools.
Daily Dose: Effect of Sotagliflozin on Heart Failure-Related Events
Semaglutide 2.4 mg Could Reduce US Obesity by Half, Prevent 1.5 million CVD Events
More than 90 million adults in the US with overweight/obesity are candidates for weight loss treatment with semaglutide 2.4 mg, according to a new study.
NIH Designates Centers of Excellence to Improve Maternal Health Equity
The newly named centers across the country will work closely with communities to focus research on populations at greatest risk for perinatal morbidity and mortality.
Daily Dose: Daily Sugared Drink Intake & Risk of Hepatic Morbidity, Mortality in Postmenopausal Women
Amazon Pharmacy Announces Insulin Discounts with Automatic, Manufacturer-sponsored Coupons
Patients with diabetes will be able to save money when ordering insulin and commonly prescribed products, such as continuous glucose monitors and pumps.
Sotagliflozin Cut Risk by >50% for HF Rehospitalization and CV Death when Started Before Discharge
A post hoc analysis of the landmark SOLOIST-WFH trial supports avoiding delay in initiating the SGLT-2/1 inhibitor as part of guideline-recommended treatment.
Daily Dose: Diabetes- and CVD-Related Death Increase After 10-Year Decline
Daily Dose: Vegetarian Diet Boosts Optimal Drug Therapy in High-Risk CVD Patients
Insulin Prescription Fills Up Following Inflation Reduction Act Cap on Out-of-Pocket Costs
The new policy is helping people who are taking insulin save money and helping others to afford it in the first place, says a study coauthor from the USC Sol Price School of Public Policy .
Mean Weight Loss with Tirzepatide Reaches 26% Across 2 Pivotal Phase 3 Clinical Trials
In adults with obesity or overweight plus comorbidities but without T2D once-weekly tirzepatide was associated with significant and durable weight loss vs placebo.
Vegetarian Diet May Augment Effects of Optimal Drug Therapy in Patients at High Risk of CVD
Reductions in LDL-C, HbA1c, and body weight were associated with a variety of vegetarian diets in participants with or at high risk for cardiovascular disease.
Social Determinants of Health and Prevention of Cardiovascular Disease
Methods proven to prevent ASCVD may fall short in certain populations if the impacts of SDOH are not closely monitored. The ACC/AHA provide considerations for 7 health domains.
Diabetes- and CVD-Related Mortality Rise after Steady 10-Year Decline
Since 2014, the age-adjusted mortality rate for diabetes and CVD has increased by 1% after an overall decline between 1999 and 2019, new research finds.